In a four-part clinical trial program, researchers are assessing the safety and efficacy of otilimab with placebo in RA patients, along side conventional treatments, such as tofacitinib, and DMARDs…
ACR Prepares to Submit Rheumatoid Arthritis Alternative Payment Model
The ACR will soon submit the updated Rheumatoid Arthritis Alternative Payment Model to the Physician-Focused Payment Model Technical Advisory Committee for review and feedback.
Asthma, Allergic Disease, Passive Smoke Exposure & the Risk of RA
Rheumatoid arthritis (RA) is one of the most common autoimmune diseases. One hypothesis is that inflammation in the respiratory tract results in autoantibody formation that later leads to disease. Kronzer et al. set out to narrow the knowledge gaps related to the oral-respiratory factors that may mediate RA pathogenesis.
Baricitinib: Early vs. Late Treatment Outcomes in RA Patients
Recent research found that RA patients who began treatment with baricitinib experienced greater improvement from baseline than patients who began treatment with methotrexate…
A More Complicated Pregnancy: Inflammatory Arthritis Increases the Risk for Adverse Outcomes
Pregnant women with inflammatory arthritis may have an increased risk for preterm delivery. New research examined the risk of preterm delivery and other pregnancy complications in women with RA and JIA vs. healthy controls…
RheumPAC Advocates for Department of Defense Arthritis Research Funding
The ACR’s nonpartisan political action committee is continuing to advocate for increased defense department funding for rheumatology research. Learn about RheumPAC’s efforts and how you can help.
RA Patients May Safely Stop Methotrexate in Tofacitinib Combination Therapy
RA patients who achieve low disease activity on tofacitinib and methotrexate combination therapy can safely cease methotrexate use, according to recent research…
Subcutaneous CT-P13 Injection Evaluated for Safety & Efficacy of in RA Patients
Results from a one-year study suggest subcutaneous CT-P13, which is biosimilar to infliximab, is as safe and effective for RA patients as intravenous (IV) CT-P13 and IV infliximab…
Upadacitinib + Methotrexate & Other csDMARDs in RA Patients
A post-hoc analysis showed upadacitinib is safe and effective for treating RA patients when used with methotrexate or non-methotrexate csDMARDs…
The Rescue: Moving RA Patients from Adalimumab to Baricitinib
The phase 3, RA-BEAM study found RA patients who were switched from adalimumab to baricitinib experienced improvements in disease control even in the absence of an adalimumab washout. In the study, the change was not associated with an increase in adverse events or infections…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 30
- Next Page »